Long-term life satisfaction in transplant recipients
Long-term life satisfaction of patients who underwent HCT for childhood diseases is comparable to that of healthy controls, according to a new study. Researchers compared the responses to life satisfaction questionnaires of 55 long-term HCT survivors (10 or more years post-transplant, median age 25 years) with a control group of 98 young adults (median age 24 years). A 30-item questionnaire assessed education, employment, leisure time, social relationships, and perception of physical status. In a multivariate analysis, level of life satisfaction was not significantly correlated with sociodemographic factors or with HCT status. The authors conclude that patients who underwent HCT in childhood have no significant difference in life satisfaction compared with healthy controls once they reach adolescence or young adulthood.
Marrow, PBSC show comparable survival in reduced-intensity HCT
A retrospective study comparing outcomes of reduced-intensity hematopoietic cell transplantation (HCT) in adults with acute myelogenous leukemia (AML) in complete remission has found comparable leukemia-free survival (LFS) in patients transplanted using marrow or PBSC. Researchers analyzed outcomes of unrelated marrow (n=94) or PBSC (n=508) transplants performed between 2000-2007 at 123 European transplant centers. Two-year LFS was comparable in the marrow and PBSC groups: 43% vs. 46%, respectively (p=ns). Grade II-IV acute GVHD was significantly higher in the PBSC group than in the marrow group: 27% vs. 12%, respectively (p<0.002). Relapse was significantly higher in the marrow compared to the PBSC group: 46% vs. 32%, respectively (p=0.014).
Donor age has significant impact on HCT outcomes in MDS
Using younger (<30 years) HLA-matched unrelated donors results in better transplant outcomes compared to outcomes using matched related donors in patients with myelodysplastic syndromes (MDS), according to a new study. Researchers analyzed outcomes of 555 related and 164 unrelated donor transplants performed between 1999-2008 and reported to the European registry. Median donor age was 56 years (range, 35-78) in the related donors, and 34 years (range, 19-64) in unrelated donors. Transplant from younger (<30 years) unrelated donors resulted in a significantly higher 5-year overall survival compared to matched related donors and older (>30 years) unrelated donors: 40% vs. 33% vs. 24%, respectively (p=0.04).
An analysis of the patient- and disease-related factors that influence the costs of autologous and allogeneic HCT in the U.S. and Europe. The authors reviewed 14 studies examining transplant costs and found that costs ranged from $36,000-$88,000 for a single autologous transplantation to $200,000 or more for an allogeneic myeloablative transplant using an unrelated donor. Cost factors examined included pharmacy costs, patient characteristics, transplant center experience, types of conditioning, graft types, transplant complications, and duration of hospitalization.
Have experts discuss your challenging AML or MDS case during the NMDP Friday Satellite Symposium Preceding the 54th ASH Annual Meeting, Treatment of AML and MDS in Older Patients: A Case-Based Approach.
View a free webinar on newly updated guidelines for long-term follow-up care of HCT recipients, with practical advice on how to implement the guidelines into clinical practice. Access webinar » Plus, get the updated guidelines through a mobile app »
Resources For Your Patients
Webinar: Post-Transplant Living
Share this webinar with your patients to help them understand new post-transplant guidelines, recognize the importance of maintaining a healthy lifestyle and hear real-life tips from transplant recipients and Dr. Navneet Majhail. Access webinar »
Visit Us Online
Access outcomes data slides, CME, clinical references, patient education and more.
Advances in Transplantation is an electronic newsletter published monthly by the National Marrow Donor Program (NMDP). This newsletter is sent only to those individuals who have requested to receive clinical education updates from NMDP.
If this e-mail message was forwarded to you and you'd like Advances in Transplantation delivered directly to you, please subscribe.
If you are a member of the NMDP Be The Match Registry®, unsubscribing to the Advances in Transplantation e-newsletter does not change your status on the registry. The NMDP may still contact you by e-mail, postal mail or telephone if a patient needs you or to request that you update your address.